Should Tumor Mitotic Rate and Patient Age, As Well As Tumor Thickness, be Used to Select Melanoma Patients for Sentinel Node Biopsy?
- 1 March 2004
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 11 (3) , 233-235
- https://doi.org/10.1245/aso.2004.01.912
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-UpAnnals of Surgical Oncology, 2004
- Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic ModelAnnals of Surgical Oncology, 2004
- Correlation Between Prognostic Factors and Increasing Age in MelanomaAnnals of Surgical Oncology, 2004
- Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma PatientsAnnals of Surgical Oncology, 2003
- Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanomaCancer, 2003
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 sydney classificationPathology, 1986
- Mitosis counting—A need for reappraisalHuman Pathology, 1981
- The classification of malignant melanoma and its histologic reportingCancer, 1973